Barani Kumar Rajendran
Associate Research Scientist in PathologyDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
Yale School of Medicine
BML, Room 113
New Haven, CT 06510
United States
About
Titles
Associate Research Scientist in Pathology
Appointments
Pathology
Associate Research ScientistPrimary
Other Departments & Organizations
Research
Overview
Bioinformatics; Next Generation Sequencing (NGS), Single-cell Research; Precision medicine; Cancer Immunology, Computational Biology; Genomics; Computational Structural Biology, Spatial Transcriptomics.
ORCID
0000-0001-9675-7718- View Lab Website
Schalper Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Barani Kumar Rajendran's published research.
Publications Timeline
A big-picture view of Barani Kumar Rajendran's research output by year.
Kurt Schalper, MD, PhD
Dianqing (Dan) Wu, PhD
Hongyue Zhou
Julie Goodwin, MD
Kishu Ranjan, PhD
Wenwen Tang, PhD
32Publications
777Citations
Publications
2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
Zhang J, Rajendran B, Desai S, Gibson J, DiPalermo J, LoRusso P, Kong Y, Zhao H, Cecchini M, Schalper K. High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties. Journal For ImmunoTherapy Of Cancer 2025, 13: e011653. PMID: 40935566, DOI: 10.1136/jitc-2025-011653.Peer-Reviewed Original ResearchThis study shows that high MGMT expression in colorectal cancer is linked to aggressive behavior, distinct genomic features, immune evasion, and shorter survival, highlighting its potential as a biomarker for prognosis and therapeutic targeting.Phyto-Fabrication Tribulus terrestris Mediated Iron Oxide Nanoparticles: A Promising Approach of Antioxidant and Anticancer Activities via in vitro and in silico Studies
Renugopal R, Palaniyandi T, Rajendran B, Kaliamoorthy S, Ravi M, Baskar G, Wahab M, Surendran H, Nannan M, Govindaraj M, Sivaji A, Al-Qahtani W, Ayub R. Phyto-Fabrication Tribulus terrestris Mediated Iron Oxide Nanoparticles: A Promising Approach of Antioxidant and Anticancer Activities via in vitro and in silico Studies. Frontiers In Bioscience-Landmark 2025, 30: 25164. PMID: 40613274, DOI: 10.31083/fbl25164.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAdenomatous polyposis coliRegulation of cell migrationColon cancer cellsInhibit cancer cell proliferationHCT-116Cancer cell proliferationBinding affinityVibrating sample magnetometryIron nanoparticlesColon cancerWound pathogensCell migrationInhibitory zoneMolecular docking studiesIn silico studiesCancer cellsDenaturation studiesPolyposis coliHydrogen peroxideScanning electron microscopyDocking studiesAntimicrobial activityEffect of anticancerProteinMG-63Editorial: Unveiling inflammaging – mechanistic insights on aging and related diseases
Satyanarayanan S, Rajendran B. Editorial: Unveiling inflammaging – mechanistic insights on aging and related diseases. Frontiers In Medicine 2025, 12: 1607050. PMID: 40330777, PMCID: PMC12052547, DOI: 10.3389/fmed.2025.1607050.Peer-Reviewed Original ResearchAltmetricThe molecular determinants regulating redox signaling in diabetic endothelial cells
Srivastava S, Kopasz-Gemmen O, Thurman A, Rajendran B, Selvam M, Kumar S, Srivastava R, Suresh M, Kumari R, Goodwin J, Inoki K. The molecular determinants regulating redox signaling in diabetic endothelial cells. Frontiers In Pharmacology 2025, 16: 1563047. PMID: 40290438, PMCID: PMC12023289, DOI: 10.3389/fphar.2025.1563047.Peer-Reviewed Original ResearchCitationsAltmetricConceptsReactive oxygen speciesProcess of oxidative phosphorylationAberrant activation of mTOR signalingNutrient-sensing kinaseCellular signaling pathwaysCellular ROS levelsLoss of AMPKOxygen speciesActivation of mTOR signalingReactive oxygen species productionIncreased ROSTranscription of pro-inflammatory cytokinesActivation of MAPKCell powerhouseGenerate ATPCell oxidative statusRenal endothelial cellsOxidative phosphorylationRedox signalingDamaged DNASignaling pathwayMolecular determinantsMTOR signalingPI3KAberrant activationIL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer
Ranjan K, Rajendran B, Deen I, Costantini A, de Rodas M, Desai S, Scallo F, Gianino N, Ferrone S, Schalper K. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Molecular Cancer 2025, 24: 80. PMID: 40091029, PMCID: PMC11912681, DOI: 10.1186/s12943-025-02276-z.Peer-Reviewed Original ResearchThis study investigates IL-4's role in TAP2 downregulation as a reversible mechanism of immune evasion and resistance to immunotherapy in non-small cell lung cancer, highlighting potential therapeutic strategies to restore TAP2 expression and enhance treatment efficacy.
2024
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava S, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran B, Setia O, Aryal B, Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, Fernández-Hernando C, Shulman G, Goodwin J. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances 2024, 10: eadn6068. PMID: 39630889, PMCID: PMC11616692, DOI: 10.1126/sciadv.adn6068.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAngiopoietin-like 4Diabetic kidney diseaseIntegrin B1Fibrogenic moleculesMutant miceSTING pathway activationIncreased fatty acid oxidationProgressive diabetic kidney diseaseDiabetic kidneyKidney diseaseReduced epithelial-to-mesenchymal transitionEpithelial-to-mesenchymal transitionFatty acid oxidationExpression of pro-inflammatory cytokinesTargeted pharmacological therapiesGene expressionMitochondrial damageEndothelial-to-mesenchymal transitionPro-inflammatory cytokinesPathway activationPharmacological therapyControl miceIntegrinAcid oxidationFibrogenic phenotypeAdvances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutationsP3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade
Chiang A, Matera R, Ashley K, Rajendran B, Schalper K. P3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade. Journal Of Thoracic Oncology 2024, 19: s362. DOI: 10.1016/j.jtho.2024.09.652.Peer-Reviewed Original ResearchWnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis
Luan Y, Hu J, Wang Q, Wang X, Li W, Qu R, Yang C, Rajendran B, Zhou H, Liu P, Zhang N, Shi Y, Liu Y, Tang W, Lu J, Wu D. Wnt5 controls splenic myelopoiesis and neutrophil functional ambivalency during DSS-induced colitis. Cell Reports 2024, 43: 113934. PMID: 38461416, PMCID: PMC11064424, DOI: 10.1016/j.celrep.2024.113934.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCD8+ T cell activationNeutrophil productionNeutrophil plasticitySplenic extramedullary myelopoiesisFamily member 5T cell activationInnate immune cellsSplenic stromal cellsDSS-Induced ColitisAnti-inflammatory protectionCD101 expressionPro-inflammatory activitySplenic myelopoiesisExtramedullary myelopoiesisBone marrowImmune cellsSplenic neutrophilsMember 5Autoimmune diseasesInflammatory outcomesCell activationStromal cellsColitisSplenic productionElevated numbersThe CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
Liao X, Li W, Zhou H, Rajendran B, Li A, Ren J, Luan Y, Calderwood D, Turk B, Tang W, Liu Y, Wu D. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. Nature Communications 2024, 15: 603. PMID: 38242867, PMCID: PMC10798966, DOI: 10.1038/s41467-024-44885-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD8+ T cellsT cellsCancer immunotherapyMouse CD8+ T cellsAnti-tumor immunityTumor growth inhibition abilityAnti-tumor effectsInhibition of neddylationCD8Effector functionsTCR stimulationIL2 signalingCentral signaling pathwaysCore signaling pathwaysEffector activityNegative regulatory mechanismsTranslational implicationsImmunotherapyGrowth inhibition abilityCytokine signalingTCRProteomic alterationsSignaling pathwayCancerCRISPR-based screens
Academic Achievements & Community Involvement
Activities
activity Frontiers in Medicine
2022 - PresentJournal ServiceGuest Editoractivity Pharmacognosy Magazine
2022 - PresentJournal ServiceEditorial Board Memberactivity Frontiers in Bioinformatics
2022 - PresentJournal ServiceGuest Editoractivity Scientific Reports
2024 - PresentJournal ServiceRevieweractivity Frontiers in Oncology
2022 - PresentJournal ServiceReviewer
Links
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
BML, Room 113
New Haven, CT 06510
United States